Results 121 to 130 of about 574,820 (293)

'To hell with it': a case study examination of organisational trustworthiness, and dependent stakeholder-organisation relations in the Milaki plant [PDF]

open access: yes, 2015
This paper investigates trust worthiness and dependent stakeholder relations with a contextualised case-study of the Milaki plant in Greece, owned and operated by a multinational concrete aggregates firm.
Kougiannou, K, Wallis, M
core  

Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24‐Month Follow‐Up From the Italian Registry

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Onasemnogene abeparvovec (OA) is an AAV9‐based gene therapy for spinal muscular atrophy type I (SMA I). Real‐world outcomes show increased response variability compared to clinical trials, and follow‐up data beyond 12–18 months are limited.
Marika Pane   +43 more
wiley   +1 more source

Key Insights and Priorities for Evaluating the Effectiveness of Clinical Ethics Consultation

open access: yesCanadian Journal of Bioethics
During the 2023 Canadian Bioethics Society forum, 28 practicing healthcare ethicists (PHEs) and other attendees from across Canada, including bioethics students and fellows, gathered virtually for a collaborative workshop entitled “Towards Evaluating ...
Lauren Honan   +4 more
doaj   +1 more source

Quantifying the Impact of Ocrelizumab on Paramagnetic Rim Lesions in Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Paramagnetic rim lesions (PRLs) are a subset of chronic active multiple sclerosis (MS) lesions marked by iron‐laden microglia and macrophages. Ocrelizumab, a monoclonal antibody targeting CD20+ B cells, suppresses acute MS activity, but its effect on PRLs remains unclear. In a longitudinal study of 29 ocrelizumab‐treated patients with at least
Kimberly H. Markowitz   +8 more
wiley   +1 more source

Reperfusion‐Dependent Outcomes After Endovascular Thrombectomy Stratified by NIHSS‐ASPECTS Clinical‐Core Mismatch

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This analysis evaluates the effect of successful reperfusion on functional outcomes after MT, stratified by admission National Institutes of Health Stroke Scale (NIHSS) and Alberta Stroke Program Early CT Score (ASPECTS) as surrogates for clinical‐core mismatch, using multicenter registry data.
Felix Schlicht   +53 more
wiley   +1 more source

Ethics Consultation in Oncology: The Search for Quality in Quantity. [PDF]

open access: yesJCO Oncol Pract, 2022
Marron JM   +3 more
europepmc   +1 more source

Cracking the Code: Genotype–Phenotype Correlation Models in Sarcoglycanopathies

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Sarcoglycanopathies are among the most severe limb‐girdle muscular dystrophies (LGMD), though milder presentations have been described. These diseases are primarily caused by missense variants, but the limited predictability of their effect on protein maturation, complex formation, and transport has hindered reliable genotype ...
Leonela Luce   +72 more
wiley   +1 more source

Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. ABSTRACT Objective Return of disease activity is expected when patients discontinue disease‐modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher‐than‐expected disease activity (rebound) after discontinuation.
Ralf Gold   +12 more
wiley   +1 more source

Hermeneutika Fazlur Rahman: Upaya Membangun Harmoni Teologi, Etika, Dan Hukum [PDF]

open access: yes, 2011
:Fazlur Rahman's Hermeneutics: An effort to Build Harmony Between Theology, Ethics and Law.This paper attempts to discuss the hermeneutical theory proposed by Fazlur Rahman.
Syamruddin, S. (Syamruddin)
core  

Home - About - Disclaimer - Privacy